Position in LLY
as of Jun 30, 2026
· filed Aug 25, 2026
Position Value
$171,688,823
+$50,117,305 QoQ
Shares Held
143,142
+8.3% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
2.13%
of 13F equity value
Holder Rank
#287
of 4,621 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 97%
Shared 0%
None 3%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Groupe la Francaise holds $505,348,073 across 12 Drug Manufacturers - General names. LLY ranks #1 (34.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
143,142 | $171,688,823 | |
| 2 | AZN |
Astrazeneca PLC
|
810,732 | $153,731,001 | |
| 3 | ABBV |
AbbVie Inc.
|
303,838 | $76,457,794 | |
| 4 | JNJ |
Johnson & Johnson
|
198,681 | $50,459,013 | |
| 5 | MRK |
Merck & Co., Inc.
|
260,892 | $33,524,622 | |
| 6 | OGN |
Organon & Co.
|
775,382 | $10,498,672 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
49,627 | $6,269,875 | |
| 8 | GRFS |
Grifols SA
|
238,928 | $1,691,610 |
All Filings in LLY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $171,688,823 | 143,142 | Shares | Defined | 2026-08-25 | |
| 2026-03-31 | $121,571,518 | 132,176 | Shares | Defined | 2026-05-21 | |
| 2025-12-31 | $145,879,225 | 135,742 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $140,835,303 | 184,581 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $140,947,598 | 180,811 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $89,593,889 | 108,479 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $85,984,588 | 111,379 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||